S
arcopenia initially referred to loss of skeletal muscle mass with aging, 1 but loss of muscle mass alone is weakly correlated with poor physical performance and disability. 2 Therefore, the definition of sarcopenia has evolved to describe loss of muscle mass combined with loss of muscle function. Sarcopenia is associated with several negative health outcomes, including disability, falls, fractures, and hospitalization-all of which lead to higher healthcare costs for older adults. 3 One study estimated that, in 2000, $18 billion in healthcare costs were related to sarcopenia. 4 Sarcopenia is an important health problem in the older adult population. Recent efforts to understand the prevalence of sarcopenia and its relationship to functional loss in older adults led to the attribution of an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) code to the syndrome in 2016. To fully understand the prevalence of sarcopenia, its effect on individuals and the healthcare system, and the optimal treatment options available, we must first understand how to diagnosis it.
There is no universally accepted standard diagnostic criteria for sarcopenia. Several working groups have convened to develop recommendations for the assessment and identification of sarcopenia in older adults. Two such groups are the European Working Group on Sarcopenia in Older People (EWGSOP) and more recently the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. The EWGSOP and FNIH Sarcopenia Project had differing approaches to developing their recommendations for diagnosing sarcopenia. The EWGSOP defined sarcopenia as low muscle mass combined with low muscle strength or poor physical performance. 5 It developed guidelines for assessing each component of sarcopenia (muscle mass, strength, function) based on accuracy and availability of techniques in research and clinical settings. Cut-points were determined based on previous studies in healthy young adult populations. The FNIH Sarcopenia Project took a slightly different approach and considered low physical performance to be an outcome of sarcopenia. 6 It sought to determine what values of muscle mass and muscle weakness were correlated with poor physical performance (slow walking), rather than developing cut-points based on normative data. [6] [7] [8] [9] [10] Therefore, the FNIH definition of sarcopenia includes only low muscle mass combined with low muscle strength. Application of these consensus panel recommendations to regular clinical practice can be difficult because of the resources needed for assessment. In light of these challenges, the SARC-F questionnaire was developed as a screening tool to provide a simple, efficient method of identifying individuals with sarcopenia during regular office visits.
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Even though there has been much progress in defining and diagnosing sarcopenia, questions still remain. Consensus panel criteria were developed using data from relatively healthy, community-dwelling older adults. [5] [6] [7] [8] [9] [10] The SARC-F has predominantly been tested in independent older adults. [12] [13] [14] Community-dwelling adults are likely to have better functional abilities than the typical long-term care resident with multiple medical conditions and limited independence. Few studies have examined prevalence estimates and agreement between different sarcopenia criteria in older adults residing in long-term care communities, despite the arguably greater clinical relevance of this population. The objective of our study was to apply several current sarcopenia diagnostic criteria and examine their performance in a long-term care population. We aimed to establish the prevalence of sarcopenia based on each of the criteria, determine the overlap between the EWSOP and FNIH criteria for identifying sarcopenia in a longterm care cohort, and calculate the sensitivity and specificity of the SARC-F questionnaire as a convenient screen in comparison with each consensus panel diagnostic criteria for sarcopenia.
METHODS

Study Design and Population
This study was a secondary cross-sectional analysis. We included 141 women aged 65 and older residing in a longterm care facility in the greater Pittsburgh, Pennsylvania, area. Women with a life expectancy of less than 3 years, those with known neuromuscular disorders, and those who could not walk 4 m to assess gait speed were excluded. Presence of comorbid conditions 15 and frailty status 16 were assessed to describe participants' overall health and functional status. Data were collected during eligibility screening for an ongoing fracture reduction trial approved by the University of Pittsburgh institutional review board. Written informed consent was obtained from participants or their representatives.
Sarcopenia Assessment
Appendicular lean muscle mass (ALM) was measured in grams using whole-body dual x-ray absorptiometry (DXA) (Discovery A, Hologic, Bedford, MA). Grip strength was measured in kilograms using a dynamometer (Jamar Plus, Sammons Preston, Bolingbrook, IL). Three measurements were taken with each hand, and the maximum grip strength over all trials was used for analysis. Average gait speed (m/s) of two trials was measured over a 4-m walk, according to established methods. 17 Body mass index (BMI; kg/m 2 ) was calculated from height and weight measurements.
Sarcopenia Classifications
Participants were identified as sarcopenic according to the EWGSOP criteria, FNIH criteria, and the SARC-F. Participants were classified as sarcopenic according to the EWG-SOP criteria for women if they had low muscle mass (ALM/height 2 ≤ 5.5 kg/m 2 ) combined with muscle weakness (grip strength < 20 kg) or low physical performance (gait speed <0.8 m/s). 5 We used 2 sets of sex-specific sarcopenia criteria from the FNIH panel recommendations. The first set (FNIH 1) followed the initial conservative cutpoint recommendations for women of ALM standardized to BMI (ALM/BMI <0.512 m 2 ) combined with muscle weakness (grip strength < 16 kg). [6] [7] [8] [9] [10] The second set of FNIH criteria (FNIH 2) used the intermediate cut-point values for women of low muscle mass (ALM/BMI <0.591 m 2 ) and weakness (grip strength <19.99 kg). 7, 18 All FNIH cut-points were derived from pooled data sets using classification and regression tree analysis. Grip strength cut-points for weakness (<16 kg) or intermediate weakness (16-20 kg) were associated with mobility impairment as assessed according to slow gait speed. 7 The FNIH 1 muscle mass cut-point was determined as the value that predicted weak grip strength (<16 kg). 8 The FNIH 2 muscle mass cut-point was derived from classification and regression tree analyses for predicting intermediate weakness. 18 The SARC-F questionnaire consisted of 5 questions about strength; ability to walk, rise from a chair, and climb stairs; and fall history. 11 Questions were scored and summed to provide an overall score ranging from 0 to 10. A SARC-F score of 4 or greater was considered to be indicative of sarcopenia. 11 Trained research personnel administered the SARC-F orally to all participants.
Statistical Analyses
We used appropriate summary statistics (means, standard deviations, frequencies, percentages) to describe participant characteristics. We constructed a 3-factor Venn diagram to graphically assess the extent of overlap between the three consensus criteria for sarcopenia. Using each of the consensus criteria as the criterion standard, we also examined the sensitivity and specificity of the SARC-F as a screening test to identify sarcopenia. SAS version 9.3 (SAS Institute, Inc., Cary, NC) was used for all statistical analyses.
RESULTS
Participant Characteristics
Participant characteristics are presented in Table 1 . Our population ranged in age from 65 to 97 (mean AE standard deviation 83.6 AE 7.0). Mean comorbidity burden was 3.1 AE 1.1, and 55.3% were frail or prefrail. Average muscle mass was above the EWGSOP and FNIH definitions for low lean muscle mass. Mean grip strength and gait speed were below the EWGSOP cut-points for muscle weakness (<20 kg) and poor physical performance (gait speed <0.8 m/s), respectively.
Prevalence According to EWGSOP and FNIH Sarcopenia Criteria
The prevalence of sarcopenia was 7.8% (n = 11) using the EWGSOP criteria, 4.3% (n = 6) according to FNIH conservative cut-point guidelines, and 32.6% (n = 46) using FNIH intermediate cut-points. Many participants met some but not all of the criteria necessary to be classified as having sarcopenia (Table 2 ). More than half of the participants had low muscle mass according to the FNIH 2 cutpoint (ALM/BMI <0.591 m 2 ), even though only 32.6% were deemed to have sarcopenia. Similar findings occurred for muscle weakness defined according to the EWGSOP and FNIH 2 definitions, with 53.2% of participants having low grip strength. According to EWGSOP guidelines, 52.5% of participants had poor physical performance as indicated by slow gait speed, but only 7.8% had sarcopenia.
Agreement Between Consensus Guidelines
There was little agreement on who had sarcopenia based on the different consensus panel definitions (Figure 1 ). Six participants were considered sarcopenic according to both FNIH definitions. The EWGSOP overlapped with FNIH 1 in the identification of 2 women and with FNIH 2 in 6 women. Only 2 women met the criteria for sarcopenia according to all 3 consensus definitions. The EWGSOP had sensitivity of 33.3% and specificity of 93.3% when compared with the FNIH 1 criteria as the criterion standard. Sensitivity of the EWGSOP criteria was lower (13.0%) with similar specificity (94.7%) when using FNIH 2 as the criterion standard.
SARC-F Questionnaire
The SARC-F questionnaire identified 30 participants (21.3%) with sarcopenia. It did not consistently identify the same participants as sarcopenic as did the EWGSOP and FNIH consensus definitions (Table 3 ). SARC-F had low sensitivity with respect to each of the consensus panel guidelines (18.2-33.3%). Specificity was better (78.7-81.1%). 
DISCUSSION
The prevalence of sarcopenia ranged from 4.3% to 32.6% according to diagnostic criteria recommended by the EWGSOP and FNIH consensus panels; however, they identified different participants, with little overlap. Prevalence of sarcopenia was 21.3% using a score of 4 or greater on the simple SARC-F questionnaire. The SARC-F had 78% specificity with the EWGSOP criterion, meaning that SARC-F could reasonably exclude those who did not have sarcopenia, but sensitivity was low (18%). We found a similar pattern when comparing the SARC-F results with each of the 2 sets of FNIH panel cut-points (specificity near 80%, sensitivity 26-34%). Our results illustrate the discrepancies between current diagnostic paradigms for identifying sarcopenia in the long-term care population and are in agreement with other studies that have found varying prevalence of sarcopenia in community-dwelling older adults with different definitions.
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Disagreement on how to diagnose sarcopenia complicates assessment of older adults. Diagnosis and intervention decisions will vary depending on the diagnostic criteria applied. The current interventions for sarcopenia include adequate nutrition with protein and vitamin D combined with resistance exercise. 20 These interventions are advisable in general and would not necessarily be harmful to individuals without sarcopenia. Nevertheless, there are new pharmacological therapies in development. 22, 23 Researchers must be able to identify sarcopenia accurately to test the effectiveness of such therapies. Likewise, adoption of standard diagnostic criteria is essential for clinicians to target pharmacological treatment to those who truly require it.
One of the major difficulties when assessing an individual for sarcopenia using the EWGSOP and FNIH criteria is simple availability and accessibility of testing resources, particularly for residents in long-term care communities. In their consensus statements, the EWGSOP and FNIH workgroups recommend whole-body DXA to measure muscle mass.
5-10 FNIH consensus cut-points for muscle mass were developed from DXA results obtained on Hologic and GE Healthcare Lunar densitometers, which are not interchangeable and may contribute to discrepancies in the cut-point results. Furthermore, in some studies, muscle mass data are measured using bioelectrical impedance analysis (BIA), which may also contribute to cut-point discrepancies. Conversion equations can be used to estimate comparable DXA results, but they must be developed for specific populations and DXA technologies. 24, 25 Muscle mass cut-point recommendations may need to be adjusted for the type of DXA technology used. Additionally, DXA scanners in a majority of facilities cannot perform the whole-body scan required to assess lean muscle mass because this is not the standard method used for clinical assessment of bone mineral density. Individuals may be required to go to a specialized facility for testing, which raises concerns about cost, scheduling, and transportation. The whole-body DXA scan is not currently a billable diagnostic test in the United States. People may be unwilling or unable to pay the greater out-of-pocket expenses associated with the whole-body DXA scan for muscle mass assessment. In addition to concerns related to accessibility and availability, the physical limitations of older adults can make the process of obtaining a wholebody DXA scan challenging.
A simple questionnaire such as the SARC-F would be an ideal screening tool for geriatricians to implement in practice. Reliability and validity of the SARC-F have been established. 14 In older Chinese people, SARC-F scores ≥ 4 were associated with poor physical performance and impaired ability to perform instrumental activities of daily living. 12 Higher SARC-F scores were also predictive of 4-year mortality in older Taiwanese adults. 26 The SARC-F has potential as a clinical tool but requires refinement to increase sensitivity and specificity. As with our current findings, several other studies have shown the SARC-F to agree with working group definitions on who does not have sarcopenia but low consensus about who has sarcopenia. 13, 21, 27 The SARC-F may require modification to increase concordance with current consensus definitions to better identify people with sarcopenia.
Our study had some limitations. We examined an allfemale cohort from a single greater metropolitan area that was predominantly Caucasian; therefore, our results may have limited generalizability. Performance and agreement among these criteria may be different in other populations. The diagnosis of sarcopenia in older adults, particularly those in long-term care, is challenging given the presence of chronic diseases, mobility impairments, and other factors that can affect muscle mass and function. Consensus panel definitions based on information from relatively healthy cohorts may not be appropriate for the long-term care population.
Despite these limitations, our study had several strengths. We were able to obtain lean muscle mass measures using DXA to comply with consensus panel recommendations. We used multiple criteria, including the most recent FNIH cut-points, to characterize the prevalence of sarcopenia in a long-term care population. Consensus panel definitions of sarcopenia were developed using data from previous studies that focused on community-dwelling older adults. The FNIH work group acknowledges this limitation and suggests more investigation into how their recommendations perform in populations that are less healthy and reside in long-term care communities. 9 We also compared the latest expert consensus definitions with a simple questionnaire that could be more easily integrated into clinical practice with long-term care residents. In summary, current sarcopenia diagnostic guidelines are not in agreement with one another, leading to a wide range of sarcopenia prevalence estimates even in long-term care residents, in whom sarcopenia is assumed to be more prevalent. The preferred methods of measurement that the EWGSOP and FNIH consensus panels have proposed are not always feasible in primary care or long-term care settings. Physicians can apply the ICD-10-CM code for sarcopenia without standard guidelines for how sarcopenia is determined. Given the challenges of obtaining the appropriate diagnostic measurements in clinical practice, there is a need for a screening tool to aid clinicians in identifying individuals who probably have sarcopenia, for whom further diagnostic testing is justified. The goal is to identify sarcopenia and intervene to prevent adverse health outcomes. Multiple consensus panel definitions and the SARC-F have similar modest predictive ability for adverse outcomes, 28 but our results demonstrate that the various definitions identify different individuals as having sarcopenia. It is possible that combining components from diagnostic measures and screening tools may improve the ability to predict adverse outcomes. Sarcopenia may be difficult to define objectively, but geriatricians may "know it when we see it," a characteristic shared with other geriatric syndromes such as frailty. If so, it would be valuable and clinically relevant to base identification of sarcopenia at least partially on a self-report questionnaire of functional ability. Further research is necessary to explore the optimal composite measures of sarcopenia that correlate with adverse health outcomes.
